vs
La Rosa Holdings Corp.（LRHC）与ARS Pharmaceuticals, Inc.（SPRY）财务数据对比。点击上方公司名可切换其他公司
ARS Pharmaceuticals, Inc.的季度营收约是La Rosa Holdings Corp.的1.4倍（$28.1M vs $20.2M），La Rosa Holdings Corp.净利率更高（-27.4% vs -147.1%，领先119.8%），La Rosa Holdings Corp.同比增速更快（3.2% vs -67.6%）
拉罗萨控股旗下的万拉罗萨父子通心粉公司由西西里移民文森佐·拉罗萨于1914年创立，发展至今已成为美国规模领先的区域知名食品品牌，可生产四十余种意面产品，在当地市场拥有较高的认可度。
ARS Pharmaceuticals是一家处于后期研发阶段的生物制药企业，专注于开发和商业化严重过敏反应创新疗法，核心产品为无需注射的肾上腺素鼻腔递送制剂，主要面向北美市场，服务存在致命过敏风险的成人及儿童患者群体。
LRHC vs SPRY — 直观对比
营收规模更大
SPRY
是对方的1.4倍
$20.2M
营收增速更快
LRHC
高出70.7%
-67.6%
净利率更高
LRHC
高出119.8%
-147.1%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.2M | $28.1M |
| 净利润 | $-5.5M | $-41.3M |
| 毛利率 | 8.4% | — |
| 营业利润率 | -24.7% | -147.6% |
| 净利率 | -27.4% | -147.1% |
| 营收同比 | 3.2% | -67.6% |
| 净利润同比 | -125.7% | -182.8% |
| 每股收益（稀释后） | $-5.44 | $-0.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LRHCSPRY
| Q4 25 | — | $28.1M | ||
| Q3 25 | $20.2M | $32.5M | ||
| Q2 25 | $23.2M | $15.7M | ||
| Q1 25 | $17.5M | $8.0M | ||
| Q4 24 | $17.7M | $86.6M | ||
| Q3 24 | $19.6M | $2.1M | ||
| Q2 24 | $19.1M | $500.0K | ||
| Q1 24 | $13.1M | $0 |
净利润LRHCSPRY
| Q4 25 | — | $-41.3M | ||
| Q3 25 | $-5.5M | $-51.2M | ||
| Q2 25 | $78.4M | $-44.9M | ||
| Q1 25 | $-95.7M | $-33.9M | ||
| Q4 24 | $-5.1M | $49.9M | ||
| Q3 24 | $-2.5M | $-19.1M | ||
| Q2 24 | $-2.3M | $-12.5M | ||
| Q1 24 | $-4.6M | $-10.3M |
毛利率LRHCSPRY
| Q4 25 | — | — | ||
| Q3 25 | 8.4% | — | ||
| Q2 25 | 8.0% | — | ||
| Q1 25 | 8.8% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 8.3% | — | ||
| Q2 24 | 8.3% | — | ||
| Q1 24 | 8.9% | — |
营业利润率LRHCSPRY
| Q4 25 | — | -147.6% | ||
| Q3 25 | -24.7% | -163.7% | ||
| Q2 25 | -10.6% | -302.9% | ||
| Q1 25 | -26.7% | -466.3% | ||
| Q4 24 | -17.1% | 54.5% | ||
| Q3 24 | -8.9% | -1051.6% | ||
| Q2 24 | -9.7% | -3068.0% | ||
| Q1 24 | -35.0% | — |
净利率LRHCSPRY
| Q4 25 | — | -147.1% | ||
| Q3 25 | -27.4% | -157.4% | ||
| Q2 25 | 337.8% | -285.6% | ||
| Q1 25 | -546.5% | -425.7% | ||
| Q4 24 | -28.7% | 57.7% | ||
| Q3 24 | -12.5% | -925.0% | ||
| Q2 24 | -12.2% | -2503.2% | ||
| Q1 24 | -35.1% | — |
每股收益（稀释后）LRHCSPRY
| Q4 25 | — | $-0.41 | ||
| Q3 25 | $-5.44 | $-0.52 | ||
| Q2 25 | $15.25 | $-0.46 | ||
| Q1 25 | $-5.86 | $-0.35 | ||
| Q4 24 | $28.54 | $0.52 | ||
| Q3 24 | $-16.49 | $-0.20 | ||
| Q2 24 | $-12.49 | $-0.13 | ||
| Q1 24 | $-0.35 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.0M | $245.0M |
| 总债务越低越好 | $642.8K | $96.4M |
| 股东权益账面价值 | $1.6M | $114.3M |
| 总资产 | $21.7M | $327.7M |
| 负债/权益比越低杠杆越低 | 0.41× | 0.84× |
8季度趋势，按日历期对齐
现金及短期投资LRHCSPRY
| Q4 25 | — | $245.0M | ||
| Q3 25 | $4.0M | $288.2M | ||
| Q2 25 | $5.1M | $240.1M | ||
| Q1 25 | $2.9M | $275.7M | ||
| Q4 24 | $1.4M | $314.0M | ||
| Q3 24 | $1.8M | $204.6M | ||
| Q2 24 | $1.6M | $218.7M | ||
| Q1 24 | $1.1M | $223.6M |
总债务LRHCSPRY
| Q4 25 | — | $96.4M | ||
| Q3 25 | $642.8K | $96.2M | ||
| Q2 25 | $644.3K | — | ||
| Q1 25 | $645.9K | — | ||
| Q4 24 | $647.6K | $0 | ||
| Q3 24 | $649.2K | — | ||
| Q2 24 | $650.8K | — | ||
| Q1 24 | $652.4K | — |
股东权益LRHCSPRY
| Q4 25 | — | $114.3M | ||
| Q3 25 | $1.6M | $147.7M | ||
| Q2 25 | $3.4M | $192.3M | ||
| Q1 25 | $-87.5M | $229.0M | ||
| Q4 24 | $2.6M | $256.8M | ||
| Q3 24 | $5.0M | $201.0M | ||
| Q2 24 | $4.7M | $215.2M | ||
| Q1 24 | $5.6M | $223.9M |
总资产LRHCSPRY
| Q4 25 | — | $327.7M | ||
| Q3 25 | $21.7M | $372.8M | ||
| Q2 25 | $22.9M | $313.5M | ||
| Q1 25 | $21.0M | $327.3M | ||
| Q4 24 | $19.4M | $351.2M | ||
| Q3 24 | $19.7M | $217.6M | ||
| Q2 24 | $18.7M | $222.0M | ||
| Q1 24 | $16.3M | $227.6M |
负债/权益比LRHCSPRY
| Q4 25 | — | 0.84× | ||
| Q3 25 | 0.41× | 0.65× | ||
| Q2 25 | 0.19× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.25× | 0.00× | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.12× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.3M | $-43.5M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流LRHCSPRY
| Q4 25 | — | $-43.5M | ||
| Q3 25 | $-1.3M | $-47.0M | ||
| Q2 25 | $-1.4M | $-39.6M | ||
| Q1 25 | $-3.5M | $-40.7M | ||
| Q4 24 | $-1.1M | $42.0M | ||
| Q3 24 | $-591.6K | $-14.5M | ||
| Q2 24 | $-803.1K | $-7.3M | ||
| Q1 24 | $-538.3K | $-6.7M |
自由现金流LRHCSPRY
| Q4 25 | — | — | ||
| Q3 25 | — | $-47.2M | ||
| Q2 25 | — | $-39.6M | ||
| Q1 25 | — | $-40.8M | ||
| Q4 24 | — | $41.7M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | — | $-7.3M | ||
| Q1 24 | — | $-6.8M |
自由现金流率LRHCSPRY
| Q4 25 | — | — | ||
| Q3 25 | — | -145.4% | ||
| Q2 25 | — | -252.2% | ||
| Q1 25 | — | -512.1% | ||
| Q4 24 | — | 48.2% | ||
| Q3 24 | — | -706.3% | ||
| Q2 24 | — | -1463.4% | ||
| Q1 24 | — | — |
资本支出强度LRHCSPRY
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 7.6% | ||
| Q1 24 | — | — |
现金转化率LRHCSPRY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LRHC
| Real Estate Residential Brokerage Services | $16.8M | 83% |
| Transferred Over Time | $3.5M | 17% |
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
